National Guideline Clearinghouse | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

National Guideline Clearinghouse | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

National Institute for Health and Care Excellence (NICE)

• Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. This updates a previously published guideline summary.

Guideline Title Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Bibliographic Source(s) National Institute for Health and Care Excellence (NICE). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Jan 26. 81 p. (Technology appraisal guidance; no. 375).  Guideline Status This is the current release of the guideline. This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Certolizumab pegol for the treatment of rheumatoid arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Feb. 31 p. (Technology appraisal guidance; no. 186). This guideline meets NGC's 2013 (revised) inclusion criteria.